Purpose: Dry eye disease (DED) is a common ocular disease that can have adverse effects on quality of life. Our aim was to develop a single-item questionnaire that is reliable, patient-driven, and clinic friendly to assess DED symptoms and their effect on quality of life to help support the management of patients with DED.
D ry eye disease (DED) is a common ocular disease that affects 5% to 17% of the US population with prevalence increasing with age. [1] [2] [3] It is a chronic disease characterized by symptoms such as ocular pain, grittiness, burning, foreign body sensation, tearing, and sensitivity to light. 4, 5 Multiple studies have confirmed that DED adversely affects a person's quality of life (QOL). 1, [5] [6] [7] [8] [9] Specifically, DED symptoms can affect a person's ability to read comfortably, concentrate, operate a computer, drive, or even perform basic work tasks. 1 Moreover, the adverse effects on QOL typically become more pronounced with disease chronicity and symptom severity. 9 Two recent studies used utility assessments, a type of QOL measure, to quantify DED's effect on a patient's QOL. The studies demonstrated that patients with moderate-to-severe dry eye have utility scores comparable to those who have chronic conditions such as kidney failure requiring dialysis, severe angina, and hip fractures. 3, 10 This finding is strong evidence that QOL and symptom severity are interrelated. Both need to be addressed when treating patients with dry eye to maximize health outcome and patient-physician satisfaction.
With the increasing recognition that DED symptoms diminish QOL, multiple dry eye questionnaires have been developed to evaluate both dry eye symptoms and their effect on QOL. Many of these questionnaires, however, either have not undergone sufficient validity and reliability testing or are not specific to DED. 4, 6 In fact, a recent review of dry eye questionnaires revealed only 2 validated and reliable diseasespecific questionnaires that accounted for both DED symptoms and QOL: the Ocular Surface Disease Index (OSDI) 11 and the Impact of Dry Eye on Everyday Life (IDEEL). 12, 13 The OSDI and IDEEL have both proven extremely valuable in assessing dry eye symptoms and disease effect on QOL in clinical trials. 2, [4] [5] [6] 8, 9, 14 The IDEEL, however, contains 57 items and the OSDI, a 12-item questionnaire, involves a complex, timeconsuming scoring algorithm. 11, 12, 14 Therefore, both questionnaires are time-consuming to complete and score, and may have limitations being implemented into a busy clinical setting. 11, 12, 14 In addition to the administrative and scoring burdens of the OSDI and IDEEL, clinical markers for DED, such as fluorescein staining, tear break-up time (TBUT), and Schirmer testing, have high interobserver biases, lack standardization among ophthalmologist providers, and correlate poorly with subjective symptoms. 4, 6, 7, 15 Consequently, physician and patient ratings of dry eye status and its effect on QOL are often discordant. It is essential that physicians take this discordance into account when attempting to treat a patient's dry eye because clinical signs alone may not fully capture the patient's experience with DED. If a busy clinical practice does not allow a clinician the necessary time to administer the OSDI or IDEEL, however, this discordance may not be detected and a patient's symptoms may go untreated. 1, 5, 7, 13 Thus, there is a pressing need to produce a more efficient and reliable patient-driven instrument that physicians can use to help guide therapy and management of DED. 3 In response to this need, our research team developed a single-item dry eye questionnaire called the University of North Carolina Dry Eye Management Scale (UNC DEMS). Following the Patient-Reported Outcome Measurement Information System (PROMIS) guidelines for instrument development as outlined below, we created the UNC DEMS to simultaneously assess both DED symptoms and their effect on QOL in dry eye patients.
METHODS

PROMIS Standards
The US Food and Drug Administration's publication of guidelines for instrument development for patientreported outcomes measures (PROs) in 2006 spurred the paradigm shift favoring the proper development and implementation of PROs in policy and health systems. 16, 17 The PROMIS, a National Institute of Health-funded initiative, has established a set of 9 standards for instrument development, refinement, and field-testing of PROs for research and clinical use. 18 The UNC DEMS ( Fig. 1 ), a 1-item, graded scale (1-10), was developed using these PROMIS standards as a guide.
Instrument Development and Psychometric Evaluation of the UNC DEMS
To date, in this ongoing effort, we have followed the first 7 PROMIS standards for UNC DEMS instrument development. The first 5 PROMIS standards: (1) defining target concept and conceptual model, (2) generating and design of individual items, (3) constructing item pool, (4) determining item bank properties, and (5) field-testing and instrument format 18 are detailed in a previous publication by the authors. 19 In brief, we used a comprehensive literature search of dry eye symptoms and disease effect on QOL combined with direct consultations with multiple ophthalmologists and dry eye patients to create an initial dry eye questionnaire. This questionnaire was administered to 18 patients with DED (International Classification of Diseases, 9th Revision, code: 375.15) followed by a 15-minute cognitive interviewing session. The UNC DEMS was then refined using feedback obtained from the cognitive interviews (see Appendix, Supplemental Digital Content 1 and 2, http:// links.lww.com/ICO/A250; http://links.lww.com/ICO/A251). A final version of the UNC DEMS was produced ( Fig. 1 ).
Validity and Reliability Testing
Following the sixth and seventh PROMIS standards (validity and reliability testing), 18 we began field-testing on a larger cohort of patients to determine the validity and testretest reliability of the UNC DEMS compared with the current gold standard, the OSDI. Using the initial validation study of the OSDI as a guide, we determined that 50 patients would be an adequate sample size to estimate the intraclass correlation to within 0.06 using a 1-sided 95% confidence interval (CI) if the true correlation is 0.9 (to determine reliability of the questionnaire); in addition, we determined that this sample size would provide 98% power to detect a 0.50 correlation with the OSDI and 89% power to detect a 0.40 correlation with artificial tear use. 11 Therefore, we aimed to recruit 75 patients (with the goal of at least two thirds of those patients fully completing the study). Ultimately, a total of 66 patients were recruited into the study, of which 46 had dry eye (ICD-9 code: 375.15) and 20 were controls without DED. To be included in the dry eye group, patients had to be 18 years of age or older with a known diagnosis of dry eye. These patients must have experienced dry eye symptoms within the last 3 months before enrolling in the study. Control patients were healthy and without ocular surface disease or vision correction surgery. All study participants were English speaking as the UNC DEMS was available only in English. The exclusion criteria for both dry eye and control patients were: intraocular surgery within the past 90 days, history of corneal transplant or neurotrophic keratitis, dry eye secondary to Stevens-Johnson syndrome and/or cicatricial pemphigoid, severe conjunctival goblet cell loss or scarring conditions, congenitally absent meibomian or lacrimal glands, or active ocular infection such as blepharitis or lid margin inflammation. This study was approved by the University of North Carolina Institutional Review Board before enrolling patients.
During a regular clinic visit, consent was obtained from qualified study patients who were then asked to complete the DEMS (the word "UNC" was omitted from the questionnaire in this field test to prevent bias), OSDI, and a short survey. In this survey, patients were asked to report whether they have used artificial tears, frequency of artificial tear use, and their subjective rating of their DED status as either normal, mild-to-moderate, or severe. The study investigators also obtained TBUT and fluorescein corneoconjunctival staining (FUL-GLO, Akorn, MD). The average TBUT of both eyes was determined by taking 3 consecutive measurements of TBUT in each eye and then using the mean of these 6 measurements for our analyses. A fluorescein corneoconjunctival staining score was determined for each eye using the Oxford Grading Scale; the average of the OD and OS score for each patient was used for our statistical analyses. An attending ophthalmologist then performed a complete slit-lamp examination and provided his or her assessment of the patient DED status as being normal, mild-to-moderate, or severe. Of note, the ophthalmologist performing this assessment was masked to the UNC DEMS and OSDI patient-reported outcomes. Using his or her clinical judgment and experience, the ophthalmologist also recorded the presence or absence of ocular conditions commonly associated with DED, including chalasis, meibomian gland dysfunction, superficial punctate keratitis (SPK), lid wiper epitheliopathy, and poor lid apposition. After at least a week had passed since the clinic visit, the study participants were asked to complete the DEMS and OSDI a second time. The post-1-week forms were sent to the patients either by regular mail or by a Web-link in an e-mail. Participants were able to submit their responses either by mail or online, depending on their preferences. All participants were compensated with a redeemable $25 gift card.
Statistical Analysis
To assess criterion-related validity of the UNC DEMS, we estimated the Pearson correlation coefficients and their 95% confidence intervals using Fisher z transformation, between the DEMS, the OSDI, and other DED measures. Additionally, we plotted the DEMS against the OSDI at the clinic visit and fit a simple linear regression with 95% prediction intervals. To assess construct validity, we compared the mean DEMS scores between the DED and control patients as well as between groups based on patient and physician ratings of DED status. For these comparisons, we used nonparametric Kruskal-Wallis tests. For the comparisons across the ratings groups, we first conducted an overall test to compare across the 3 groups, and, only if the overall test was significant at the 0.05 level, we then conducted all pairwise comparisons. For test-retest reliability, we used only data from patients who provided follow-up measurements, and we applied linear mixed models to estimate the reliability coefficient along with 95% bootstrapped confidence intervals. Additionally, we created a limits of agreement plot 20 for repeated measurements of the DEMS, including only dry eye patients to avoid artificially inflating the number of zero differences. Finally, we compared the DEMS scores across groups of patients based on the presence or absence of ocular conditions using Kruskal-Wallis tests, and we fit a simple linear regression to assess the association of the DEMS score with the total number of ocular conditions. All analyses were conducted in SAS, version 9.3 (SAS Institute, Cary, NC).
RESULTS
Population Demographics
A total of 66 patients participated in the UNC DEMS validity and reliability study; 46 were dry eye patients and 20 were control participants free of ocular disease. Patients in the dry eye and control groups were similar in age range and numbers of men and women (Table 1 ). Artificial tear use was higher in the dry eye group than in the control (mean: 2.53 times per day vs. 0.15 times per day). Physicians and patients both rated the DED disease status as normal, mild-tomoderate, or severe ( Table 2 ). Physicians were less likely than patients to rate the patient's DED status as severe. Figure 2 presents a scatter plot of the DEMS against the OSDI at the clinic visit. The DEMS is correlated to the OSDI across all study participants at an estimated coefficient of 0.80 (95% CI, 0.69-0.87; P , 0.001). The DEMS was correlated to the OSDI in the dry eye group at an estimated coefficient of 0.69 (95% CI, 0.49-0.81; P , 0.001). Table 3 presents the correlations of the DEMS and OSDI with DED clinical measures. Overall, the DEMS and OSDI have similar moderate, but significant, correlations with artificial tear usage, fluorescein staining, and TBUT.
Validity Testing
In the control group, the mean DEMS score was 1.85 6 1.72; whereas in the dry eye group, it was 5.73 6 2.15 (P , 0.001). In the control group, the mean OSDI score was 9.49 6 14.18 as compared with 37.18 6 23.24 in the dry eye group (P , 0.001). The average DEMS and OSDI scores both varied significantly (P , 0.001 for each) across patients with normal, mild-to-moderate, and severe DED ( Table 4 ).
Test-Retest Reliability
Fifty-seven of 66 patients (86.4%) completed the post-1week follow-up DEMS; 55 patients (83.3%) also completed the post-1-week follow-up OSDI. The test-retest reliability coefficient of the UNC DEMS was estimated to be 0.90 (95% CI, 0.84-0.95). By comparison, the OSDI's reliability coefficient was 0.81 (95% CI, 0.70-0.91). Among dry eye patients, the mean difference between the post-1-week and clinic DEMS score was 20.24 units, and agreement was very good with only 1 value being outside the limits of agreement (Fig. 3 ).
Other Findings
On average, patients who were noted to have SPK on examination had a DEMS score of 2.80 points higher than did those without SPK (P , 0.001). Patients with poor lid apposition had an average DEMS score of 2.56 points higher than did those without poor lid apposition, but this difference was not statistically significant (P = 0.090). There was no statistically significant evidence of association between DEMS score and the presence of chalasis, meibomian gland dysfunction, or lid wiper epitheliopathy. When all 5 of these clinical findings were taken together, there was statistically significant association between the DEMS score and the total number of findings present on examination. On average, the DEMS score increased by 0.66 points for each additional finding (P = 0.016).
DISCUSSION
Our results indicate that UNC DEMS is a valid and reliable questionnaire that can help meet the growing need for a patient-centric measure of DED that is efficiently administered in a busy clinical setting. In this study, the DEMS demonstrated excellent test-retest reliability in a moderate sample size of both dry eye patients and controls. Some may suggest that the test-retest reliability is subject to question because patients filled out a mailed or online version of the questionnaire (rather than completing the questionnaire again in the clinic). Completing a mailed or e-mailed version of the questionnaire in a nonclinical setting, however, should reduce or have no effect on the test-retest reliability of the questionnaire, rather than artificially inflating it. Thus, our estimate of 0.90 for the reliability coefficient is most likely a conservative estimate. In addition, our estimate of 0.81 for the reliability coefficient for the OSDI is consistent with the estimate of 0.82 initially reported by Schiffman et al. 11 Our finding of similar reliability coefficients in the OSDI further strengthens our confidence in the test-retest reliability of the DEMS.
Our validity testing showed that the DEMS has a clear ability to discriminate between normal, mild-to-moderate, and severe DED status as defined by the patient. In addition, the DEMS was able to discriminate between normal and mild-tomoderate disease as defined by the clinician. The ophthalmologists who graded disease severity in this study only labeled 2 patients as having severe disease despite the fact that 14 patients rated their own disease status as severe. This finding is in accordance with the findings of 2 studies showing that clinicians routinely underestimate both patient symptoms and disease effect on QOL. 21, 22 Such results further highlight the discrepancy between patient and physician interpretation of disease severity in the dry eye population.
In general, correlation coefficients #0.35 are considered low correlations, coefficients 0.36 to 0.67 are considered moderate, and coefficients $0.68 are considered strong. 23 Using these definitions, the DEMS score correlated strongly with the OSDI score, the current gold standard of symptom and QOL measurement in dry eye patients. In addition, the DEMS showed moderate correlation with frequency of artificial tear use. The DEMS showed low-to-moderate correlation with clinical measures of DED status (fluorescein staining and TBUT), which is consistent with the clinical correlations of other PROs in DED such as the OSDI and IDEEL. 11, 12 It is important to note that although scores of the UNC DEMS and OSDI are highly correlated, the UNC DEMS is not a replacement for either the OSDI or IDEEL. Both the OSDI and IDEEL will likely remain valuable patient-reported measures in the clinic and especially in clinical trials. 2, [4] [5] [6] 8, 9, 14 Although both of these latter instruments have served as excellent measures of DED's effects on a patient's daily living in clinical trials, both are multiitem questionnaires that have a relatively high burden of administration for patients, and consume valuable clinic time for scoring. 11, 12, 14 Alternatively, the DEMS is a single-item questionnaire and may prove especially useful in these time-limited clinical settings. In addition, because the DEMS is a validated, reliable questionnaire, it may also serve a valuable role as an end-point in clinical trials alongside the OSDI and IDEEL, especially if either time or funding of such trials is limited.
One additional advantage of the UNC DEMS is that it includes a time frame (1-week) for patient reporting. Many current dry eye surveys neglect to include any type of time frame, which in turn could lead to wide variation in patient responses depending on whether they are trying to report current symptoms, average symptoms, or most severe symptoms. 4 For example, when a time frame is not included in a questionnaire, some patients may choose to report their worst symptoms since their last clinical visit, whereas other patients may only report what their specific symptoms are that day. The 1-week time frame in the UNC DEMS provides a reference point that allows patients to account for the fluctuations in their symptom severity over the past week while also covering a small enough period that patients can easily recall their symptoms and the overall effect on their QOL.
Our study is not without limitations. First, our sample size consisted of 66 patients at the UNC Ophthalmology Clinic. Although the recruited patient population was very diverse, our institution-specific research and moderate sample size may limit the generalizability of our questionnaire. Therefore, we encourage other researchers to perform trials at their respective institutions to test for broader generalizability of this tool. Second, the DEMS showed discriminative capability between normal, mild-to-moderate, and severe disease status as reported by the patients in this study as well as between normal and mildto-moderate physician-reported disease severity. Its ability to discriminate severe disease status (as determined by physicians), however, is unclear, because the ophthalmologists in this study labeled only 2 patients as having severe disease. More research should be performed to further validate this questionnaire's discriminative capability. Finally, if the DEMS is to be used as a disease-monitoring tool, physicians need to know what score change on the scale would constitute a minimal clinically important difference (MCID). The results of this study do not clearly demonstrate the MCID of the DEMS; a study at UNC, however, is currently underway to determine the MCID.
The UNC DEMS is currently undergoing further research. In addition to the UNC study mentioned above, we have also commenced a study of a culturally appropriate DEMS questionnaire in Spanish. These 2 studies together will help fulfill the final 2 PROMIS guidelines for PRO development of Interpretability and Language Translation/Cultural Adaption. 18 In conclusion, the UNC DEMS is a unique, singleitem questionnaire that provides a snapshot of a patient's overall experience-symptoms and QOL-with dry eye in the past week. It has excellent test-retest reliability and strong validity. Unlike more complicated, time-consuming questionnaires, the DEMS is easily understood and requires little time to administer in the clinic. 19 As dry eye is a chronic condition requiring both self-management and physicianmanagement, the UNC DEMS offers a bridge between patient and provider in working together to manage this challenging disease. Our questionnaire is available with instructions for use at https://www.med.unc.edu/ophth/for-patients/clinicalspecialties/unc-dry-eye-management-scale. It is our aim that this tool will assist physicians and their patients in the monitoring and management of DED in clinical practice.
